CMS Launches Drug Acquisition Cost Survey

Nothing gets a hospital finance team’s heart racing quite like a fresh federal survey with acronyms, drug pricing formulas, and a deadline attached. Yet that is exactly what happened when the Centers for Medicare & Medicaid Services (CMS) launched the Outpatient Prospective Payment System (OPPS) Drug Acquisition Cost Survey, often called ODACS. Behind the dry name is a very live policy fight over how Medicare should pay hospitals for costly outpatient drugs, especially those purchased through the 340B Drug Pricing Program.

At first glance, the survey looks like an administrative exercise: hospitals report what they paid for separately payable outpatient drugs. In reality, it is much bigger than a spreadsheet safari. The survey gives CMS a new data set it can use to shape future Medicare reimbursement, beginning with calendar year 2027 policy discussions. For hospitals, drug manufacturers, policy analysts, and patients who care about access to outpatient treatment, the launch matters because reimbursement formulas influence where care is delivered, which services remain financially sustainable, and how hospitals plan for the future.

This is also one of those health-policy stories where the backstory matters. CMS did not wake up one morning and decide that the country needed more drug-pricing homework. The survey is tied to long-running disputes over Medicare Part B drug payment, 340B hospitals, and a Supreme Court decision that told the government, in plain English for once, that it could not slash reimbursement for one hospital group without first conducting a proper survey of acquisition costs.

What CMS Actually Launched

CMS formally launched the 2026 OPPS Drug Acquisition Cost Survey on January 1, 2026, after establishing the survey in the calendar year 2026 OPPS and Ambulatory Surgical Center final rule. The survey was aimed at hospitals paid under the OPPS and listed on the agency’s provider table. CMS initially set the submission deadline for March 31, 2026, and later extended it to April 7, 2026. As of now, the submission window for that survey cycle is closed, but the policy implications are just getting started.

The agency’s goal was straightforward in concept but complex in execution: collect acquisition-cost data for separately payable outpatient drugs so CMS can better understand what hospitals actually pay, not just what formulas estimate they might pay. In the survey materials, CMS said the results are intended to inform future policymaking, beginning with the calendar year 2027 OPPS proposed rule. Translation: today’s reporting exercise could become tomorrow’s reimbursement reset.

Why This Survey Matters So Much

Under Medicare Part B, most separately payable drugs and biologicals are generally reimbursed at average sales price, or ASP, plus 6 percent. That formula has been the default reference point for years. But hospitals participating in the 340B program often acquire drugs at prices well below ASP, which has fueled an ongoing policy argument. Critics say Medicare should not pay hospitals the same rate if their acquisition costs are substantially lower. Hospitals counter that 340B savings help support vulnerable patients and underwrite services that would otherwise be difficult to maintain.

That tension exploded into litigation when HHS previously cut reimbursement for 340B-acquired drugs without conducting the kind of survey Congress described in statute. In 2022, the Supreme Court unanimously ruled in American Hospital Association v. Becerra that HHS acted unlawfully by varying reimbursement rates for 340B hospitals without first conducting a survey of hospitals’ acquisition costs. In other words, the Court did not say CMS could never adjust payment. It said CMS had to do its homework first.

ODACS is that homework. Or, if you prefer a less charitable metaphor, it is the pop quiz that could change future hospital drug revenue.

What Hospitals Had to Report

The survey did not ask for a vague sense of whether prices felt “high-ish.” CMS wanted line-item level detail. Hospitals were instructed to report outpatient drug acquisition costs for the period from July 1, 2024, through June 30, 2025. Reporting was done at the 11-digit outer National Drug Code level for the specified outpatient drugs on CMS’s template.

For each reported drug, hospitals had to provide four core data points: total units purchased for non-340B drugs, total units purchased for 340B drugs, total net acquisition cost for non-340B purchases, and total net acquisition cost for 340B purchases. CMS also instructed hospitals to incorporate discounts, rebates, and other financial concessions tied to specific NDCs. That means the exercise was not simply a matter of copying invoice totals. Teams had to account for price concessions, classify purchases correctly, separate 340B from non-340B transactions, and exclude drugs intended for inpatient use only or returned items.

That level of detail matters because CMS is not just looking for broad averages. It is building a data foundation that could support more targeted payment policy. The survey’s design also hints at what CMS cares about most: whether acquisition costs differ significantly by purchase channel, including 340B status, and whether those differences justify future reimbursement changes.

The Mandatory-versus-Not-Quite-Mandatory Debate

If you want a perfect example of how healthcare regulation can become a word game with billion-dollar consequences, here it is. CMS materials stated that hospitals on the provider table “are to” participate in the survey, and the FAQ said the lack of a response could itself be meaningful data for future rulemaking. At the same time, hospital groups quickly pointed out that the final rule also acknowledged the statute does not spell out specific consequences for hospitals that fail to respond.

The American Hospital Association and other organizations pushed back, arguing it was wrong for CMS or its contractor to imply that participation was legally mandatory when the statute does not expressly impose a penalty for nonresponse. That disagreement is not just rhetorical. If hospitals believe nonresponse could later be used against them in rate-setting, then the survey becomes effectively compulsory even if the law does not use that magic word. For hospitals already stretched thin, that distinction feels less academic and more like the difference between “optional reading” and “there will absolutely be a test.”

How Burdensome Was the Survey?

Quite burdensome, by CMS’s own estimate. The agency said it expected the survey to take about 80.5 hours to complete. In policy terms, that is a lot. In hospital terms, that can mean pulling pharmacy purchasing data, reconciling wholesaler records, validating 340B flags, coordinating across finance and compliance teams, testing upload files, and fixing errors that only reveal themselves after several rounds of review. Anyone who has ever tried to merge data from multiple vendor systems knows that “80.5 hours” is often the cheerful public estimate, not the emotional truth.

Consulting and hospital finance analyses emphasized that the survey would likely require custom reporting, strong internal controls, and careful decisions about how to allocate discounts that were not neatly tied to a single NDC. Hospitals with decentralized purchasing workflows or multiple outpatient sites likely faced an even harder lift. So while the survey may look clean on paper, the real-world task was closer to assembling a jigsaw puzzle where some pieces were invoices, some were rebate records, and some were hiding in an ancient spreadsheet last opened during the previous administration.

Why 340B Is Still the Elephant in the Outpatient Department

Although CMS has said the survey could inform broader payment policy and is not necessarily limited to 340B-only changes, the 340B program remains the political and financial center of gravity here. That is because the prior reimbursement dispute focused on whether Medicare was overpaying for drugs acquired at steep 340B discounts. CMS already had to issue a remedy rule after the Supreme Court struck down earlier payment cuts. The new survey creates a pathway for the agency to return to the issue with fresh data and a stronger legal footing.

For 340B hospitals, that prospect is unsettling. If CMS concludes that acquisition costs are materially lower than current reimbursement, it could propose reduced payment rates for some hospital groups or drug categories in future OPPS rules. Hospital advocates worry that lower reimbursement would weaken safety-net capacity and reduce cross-subsidization for outpatient services. Supporters of tighter payment policy argue that Medicare should not pay more than necessary simply because historical formulas have been generous.

Either way, ODACS is not a side quest. It is the setup for the next major reimbursement battle.

What This Could Mean for Medicare Payment Policy

The survey’s biggest policy significance is that it may move CMS from formula-based assumptions toward survey-based acquisition-cost evidence. That could allow the agency to argue, with more confidence and legal support, that certain reimbursement rates should be revised to better match hospitals’ actual costs. AMCP and other analysts have noted that CMS appears interested in considering multiple hospital characteristics, not just 340B status, when thinking about how survey findings might translate into payment policy.

That opens several possibilities. CMS could decide current payment is broadly appropriate and make only modest technical changes. It could propose targeted reductions for specific groups if the data show persistent gaps between acquisition cost and reimbursement. It could also use the survey to refine packaging decisions, policy modeling, or future data-collection cycles. The FAQs suggest CMS may conduct this survey roughly every four years, meaning ODACS may be less of a one-off event and more of a new feature of the reimbursement landscape.

Not the Same Thing as Medicaid’s NADAC Survey

One easy way to get lost in this topic is to confuse the OPPS hospital survey with Medicaid’s National Average Drug Acquisition Cost, or NADAC, process. They are related in spirit but different in purpose. NADAC is a Medicaid benchmark built from surveys of retail community pharmacy invoice prices and is updated weekly and published monthly. ODACS, by contrast, is a hospital outpatient survey tied to Medicare OPPS payment policy for separately payable drugs.

Why mention NADAC at all? Because it shows CMS already has experience using acquisition-cost survey methods in another part of the drug-pricing universe. That does not mean the programs are interchangeable, but it does suggest the agency is comfortable collecting invoice-based or net acquisition data to build reimbursement benchmarks. In healthcare policy, once a survey methodology proves it can walk, regulators usually see whether it can also run.

What Hospitals, Manufacturers, and Patients Should Watch Next

For hospitals, the next key checkpoint is the calendar year 2027 OPPS proposed rule, where CMS has said survey results could begin informing policy. Stakeholders will want to see whether the agency frames the data as evidence of overpayment, whether it proposes differential rates, and whether it introduces any special treatment for 340B-acquired drugs, hospital subgroups, or certain product categories.

Drug manufacturers should watch closely too. A shift in Medicare outpatient drug reimbursement can ripple through provider purchasing behavior, site-of-care decisions, and negotiations with distributors or group purchasing organizations. Revenue-cycle teams and compliance officers will also be monitoring whether CMS refines survey instructions, standardizes discount treatment, or changes how nonresponse is handled in future iterations.

Patients may never hear the phrase “11-digit outer NDC” at the dinner table, which is honestly a blessing. But they still have a stake in the outcome. When outpatient reimbursement changes, hospitals adjust service lines, infusion economics, clinic operations, and investment priorities. Drug payment policy is never just about numbers on a federal spreadsheet. It is about what care remains practical to deliver and where.

On-the-Ground Experiences: What This Survey Feels Like Inside a Hospital

To understand the experience side of this story, picture a hospital team on a Tuesday morning in January. The pharmacy buyer has invoice data in one system. The 340B team has accumulation and split-billing records in another. Finance has general ledger totals that make sense in aggregate but not at the individual NDC level. IT is being asked whether a custom report can be built fast enough to meet the deadline without accidentally turning half the dataset into alphabet soup. Nobody is bored, but nobody is exactly throwing confetti either.

For many organizations, the survey likely felt like an exercise in translation. Pharmacy teams speak in package sizes, wholesalers, and purchasing patterns. Finance teams speak in net cost, reconciliations, and audit trails. Compliance teams hear the words “340B” and immediately start checking whether every flag and classification can survive scrutiny. CMS, meanwhile, wants one clean upload. The practical challenge is that hospitals do not always store the needed information in one friendly place with a giant button labeled Generate Perfect Federal Survey File. Rude, honestly.

There is also the human side of the workload. Someone has to decide how to treat rebates that hit months later. Someone has to determine whether a drug purchase was truly intended for outpatient use. Someone has to explain why two internal reports that should match do not match, and why one of them was apparently built by a legend who no longer works there and left behind only a tab named “FINAL_final2.” These are ordinary healthcare-operations headaches, but ODACS turned them into policy-critical tasks.

At hospitals with significant 340B participation, the mood may have been especially tense. Teams likely understood that the numbers were not just descriptive; they could become evidence in a future reimbursement debate. That changes behavior. Data validation gets more serious. Leadership asks more questions. Legal and policy advisors suddenly appear in meetings that used to be attended mainly by finance and pharmacy staff. When a survey may influence millions of dollars in future payment, “close enough” stops being acceptable very quickly.

There is a lesson here that goes beyond one survey cycle. Healthcare reimbursement policy often looks abstract from the outside, but it lands on real desks, in real inboxes, with real time pressure. The launch of the CMS drug acquisition cost survey is a reminder that payment policy is built not just through statutes and court rulings, but also through operational detail. The people doing the reporting are not background characters. They are the bridge between policy theory and practical reimbursement reality.

Final Thoughts

CMS’s launch of the drug acquisition cost survey is more than a compliance update. It is a strategic move in the ongoing effort to align Medicare outpatient drug payment with acquisition-cost data, especially after the legal lessons of AHA v. Becerra. The survey gives CMS a potential evidentiary foundation for future payment changes, places hospitals under a significant reporting burden, and keeps the 340B reimbursement debate very much alive.

For now, the headline is simple: CMS launched the survey, hospitals had to wrestle with it, and the consequences are likely to show up in future OPPS rulemaking. In healthcare policy, that is how a survey becomes a signal. It starts as a form, becomes a dataset, and ends as a reimbursement fight with commas in all the scary places.